{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:34:12Z","timestamp":1790307252800,"version":"4.1.0"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n \n L-\u03b1 glycerylphosphorylcholine (\u03b1-GPC, choline alphoscerate) is used globally by individuals older than 50 years based on its potential function as a precursor of acetylcholine. However, choline has previously been linked to a higher risk of cardiovascular disease via trimethylamine-\n N<\/jats:italic>\n -oxide, a metabolite of choline by microbiota.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the association between \u03b1-GPC use and subsequent 10-year stroke risk.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A population-based, retrospective cohort study was conducted using data from the National Health Insurance Service of South Korea. Participants included men and women aged 50 years or older without underlying stroke or Alzheimer disease (N\u2009=\u200912\u202f008\u202f977).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n All participants were divided into whether they were prescribed \u03b1-GPC during 2006-2008. \u03b1-GPC users were matched with nonusers for all covariates to create a matched cohort. \u03b1-GPC use was further divided into durations less than 2, 2 to 6, 6 to 12, and more than 12 months of \u03b1-GPC prescriptions. The adjusted hazard ratios (aHRs) and 95% CIs for total stroke, ischemic stroke, and hemorrhagic stroke from January 1, 2009, to January 31, 2018, were calculated by multivariate Cox proportional hazards regression.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 12\u202f008\u202f977 individuals (6 401 965 [53.3%] women) aged 50 years or older were included in the study. The mean (SD) age was 61.6 (9.4) years for nonusers and 68.3 (10.0) years for users, and that of the matching cohort was 68.2 (9.9) years for both groups. Compared with \u03b1-GPC nonusers (n\u2009=\u200911\u202f900\u202f100), users (n\u2009=\u2009108\u202f877) had a higher risk for total stroke (aHR, 1.46; 95% CI, 1.43-1.48), ischemic stroke (aHR 1.36; 95% CI, 1.33-1.39), and hemorrhagic stroke (aHR, 1.36; 95% CI, 1.28-1.44). After matching for all covariates, \u03b1-GPC users had a higher risk for total stroke (aHR, 1.43; 95% CI, 1.41-1.46), ischemic stroke (aHR, 1.34; 95% CI, 1.31-1.37), and hemorrhagic stroke (aHR, 1.37; 95% CI, 1.29-1.46). Increasing intake of \u03b1-GPC was associated with a higher risk for total stroke in a dose-response manner.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, use of \u03b1-GPC was associated with a higher 10-year incident stroke risk in a dose-response manner after adjusting for traditional cerebrovascular risk factors. Future studies are needed to determine the possible mechanisms behind the potential cerebrovascular risk\u2013elevating effects of \u03b1-GPC.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2021.36008","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T11:06:06Z","timestamp":1637751966000},"page":"e2136008","source":"Crossref","is-referenced-by-count":36,"title":["Association of L-\u03b1 Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years"],"prefix":"10.1001","volume":"4","author":[{"given":"Gyeongsil","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Family Medicine, Seoul National University Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seulggie","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooyoung","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daein","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mount Sinai Beth Israel Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joung Sik","family":"Son","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Korea University Guro Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyuwoong","family":"Kim","sequence":"additional","affiliation":[{"name":"National Cancer Control Institute, National Cancer Center, Goyang-si, Gyeonggi-do, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seogsong","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Min","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Seoul National University Hospital, Seoul, Korea"},{"name":"Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"issue":"3","key":"zoi211011r1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.cger.2014.04.001","article-title":"Dementia and cognitive impairment: epidemiology, diagnosis, and treatment.","volume":"30","author":"Hugo","year":"2014","journal-title":"Clin Geriatr Med"},{"issue":"16","key":"zoi211011r3","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2019.4782","article-title":"Diagnosis and management of dementia: review.","volume":"322","author":"Arvanitakis","year":"2019","journal-title":"JAMA"},{"issue":"16","key":"zoi211011r4","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/S0047-6374(01)00312-8","article-title":"Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data.","volume":"122","author":"Parnetti","year":"2001","journal-title":"Mech Ageing Dev"},{"issue":"1-2","key":"zoi211011r5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jns.2012.07.003","article-title":"The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer\u2019s disease with cerebrovascular injury: interim results.","volume":"322","author":"Amenta","year":"2012","journal-title":"J Neurol Sci"},{"key":"zoi211011r6","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.3233\/JAD-140150","article-title":"The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer\u2019s Disease) trial: interim results after two years of treatment.","volume":"42","author":"Amenta","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"zoi211011r7","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.2174\/15672050113106660173","article-title":"Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent.","volume":"10","author":"Traini","year":"2013","journal-title":"Curr Alzheimer Res"},{"issue":"5","key":"zoi211011r10","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nm.3145","article-title":"Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.","volume":"19","author":"Koeth","year":"2013","journal-title":"Nat Med"},{"issue":"7341","key":"zoi211011r11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"issue":"1","key":"zoi211011r12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3945\/ajcn.116.131771","article-title":"Dietary phosphatidylcholine and risk of all-cause and cardiovascular-specific mortality among US women and men.","volume":"104","author":"Zheng","year":"2016","journal-title":"Am J Clin Nutr"},{"issue":"17","key":"zoi211011r13","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1109400","article-title":"Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.","volume":"368","author":"Tang","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi211011r14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5853\/jos.2019.00472","article-title":"Gut microbiota and ischemic stroke: the role of trimethylamine N-oxide.","volume":"21","author":"Nam","year":"2019","journal-title":"J Stroke"},{"issue":"15","key":"zoi211011r15","doi-asserted-by":"publisher","first-page":"e1283","DOI":"10.1212\/WNL.0000000000005298","article-title":"Elevated trimethylamine N-oxide related to ischemic brain lesions after carotid artery stenting.","volume":"90","author":"Wu","year":"2018","journal-title":"Neurology"},{"issue":"9","key":"zoi211011r16","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1161\/STROKEAHA.118.021997","article-title":"Serum trimethylamine N-oxide concentration is positively associated with first stroke in hypertensive patients.","volume":"49","author":"Nie","year":"2018","journal-title":"Stroke"},{"issue":"3","key":"zoi211011r17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/ije\/dyw253","article-title":"Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea.","volume":"46","author":"Cheol Seong","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"17","key":"zoi211011r18","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1001\/jama.2018.16501","article-title":"Association of blood pressure classification in Korean young adults according to the 2017 American College of Cardiology\/American Heart Association guidelines with subsequent cardiovascular disease events.","volume":"320","author":"Son","year":"2018","journal-title":"JAMA"},{"issue":"20","key":"zoi211011r19","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"zoi211011r20","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"issue":"4","key":"zoi211011r21","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/CIR.0000000000000350","article-title":"Heart disease and stroke statistics\u20142016 update: a report from the American Heart Association.","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"issue":"9","key":"zoi211011r22","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1161\/STROKEAHA.107.512632","article-title":"Risk of stroke and myocardial infarction after reduction or cessation of cigarette smoking: a cohort study in Korean men.","volume":"39","author":"Song","year":"2008","journal-title":"Stroke"},{"issue":"6","key":"zoi211011r23","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20190515","article-title":"Serum levels of Trimethylamine-N-oxide in patients with ischemic stroke.","volume":"39","author":"Rexidamu","year":"2019","journal-title":"Biosci Rep"},{"key":"zoi211011r24","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2147\/DDDT.S193424","article-title":"Formulation and bioequivalence studies of choline alfoscerate tablet comparing with soft gelatin capsule in healthy male volunteers.","volume":"13","author":"Min","year":"2019","journal-title":"Drug Des Dev Ther"},{"issue":"2","key":"zoi211011r25","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22246","article-title":"Trimethylamine N-oxide as a risk marker for ischemic stroke in patients with atrial fibrillation.","volume":"33","author":"Liang","year":"2019","journal-title":"J Biochem Mol Toxicol"},{"issue":"2","key":"zoi211011r26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002767","article-title":"Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-?B.","volume":"5","author":"Seldin","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"zoi211011r27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cell.2016.02.011","article-title":"Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk.","volume":"165","author":"Zhu","year":"2016","journal-title":"Cell"},{"issue":"3","key":"zoi211011r28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s11906-011-0195-x","article-title":"Vascular mechanisms in the pathogenesis of stroke.","volume":"13","author":"Sierra","year":"2011","journal-title":"Curr Hypertens Rep"},{"issue":"2","key":"zoi211011r29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.neuron.2010.07.002","article-title":"The science of stroke: mechanisms in search of treatments.","volume":"67","author":"Moskowitz","year":"2010","journal-title":"Neuron"},{"issue":"1","key":"zoi211011r30","first-page":"76","article-title":"The accuracy of ICD codes for cerebrovascular diseases in medical insurance claims.","volume":"33","author":"Park","year":"2000","journal-title":"J Prev Med Public Health"},{"key":"zoi211011r9","doi-asserted-by":"crossref","DOI":"10.1002\/9781119946045","volume-title":"Present Knowledge in Nutrition","author":"Erdman","year":"2012","edition":"10th Ed."},{"key":"zoi211011r2","unstructured":"Prince? M, Comas-Herrera? A, Knapp? M, Guerchet? M, Karagiannidou? M. World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future. September 21, 2016. Accessed October 21, 2021. https:\/\/www.alzint.org\/u\/WorldAlzheimerReport2016.pdf"},{"key":"zoi211011r8","unstructured":"National Institutes of Health Offiice of Dietary Supplements. Choline: fact sheet for health professionals. February 24, 2020. Accessed March 9, 2020. https:\/\/ods.od.nih.gov\/factsheets\/Choline-HealthProfessional\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2786547\/lee_2021_oi_211011_1789755050.62607.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:00:19Z","timestamp":1790262019000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2786547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.36008","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]}}}